

VU Research Portal

Immunotherapy and combined treatment approaches to angiogenesis inhibition

Wentink, M.Q.

2019

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Wentink, M. Q. (2019). *Immunotherapy and combined treatment approaches to angiogenesis inhibition*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CONTENTS

Chapter 1	General introduction and outline of the thesis	7
------------------	------------------------------------------------	---

PART I – Immunotherapy approaches to VEGF inhibition

Chapter 2	Vaccination approach to angiostatic treatment of cancer. <i>Biochim Biophys Acta. 2015 Jan 30;1855(2):155-171.</i>	23
Chapter 3	Targeted vaccination against VEGF using 3D-structured peptides elicits potent anti-angiogenic and anti-tumor activities. <i>Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12532-1253</i>	69
Chapter 4	Safety and immunogenicity of the angiostatic vaccine hVEGF ₂₆₋₁₀₄ /RFASE in cynomolgus macaques. <i>Vaccine. 2018 Apr 5;36(15):2025-2032.</i>	91
Chapter 5	A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. <i>Br J Cancer. 2016 Oct 11;115(8):940-948.</i>	113
Chapter 6	A phase I first-in-human clinical trial investigating the safety and tolerability of hVEGF ₂₆₋₁₀₄ /RFASE in patients with advanced solid tumors. <i>Ongoing study.</i>	133

Part II – Combination treatment strategies

Chapter 7	A phase I clinical trial to investigate the safety and tolerability of treatment with the low molecular weight heparin dalteparin, combined with sunitinib as first line treatment in patients with metastatic renal cell carcinoma. <i>Clin Genitourin Cancer. 2018 Feb;16(1):e1-e9.</i>	151
Chapter 8	Anti-angiogenic humoral immunity in patients with castration-resistant prostate cancer treated with allogeneic GVAX and ipilimumab. <i>In preparation, 2019</i>	169
Chapter 9	General discussion and perspectives	193
Appendices	Dutch summary	209
	List of publications	213
	Acknowledgements	215
	Curriculum vitae	219